See the DrugPatentWatch profile for keytruda

Keytruda, a medication developed by Merck & Co. for the treatment of cancer, first received approval from the U.S. Food and Drug Administration (FDA) on September 4, 2014 [1]. The drug, which is a type of immunotherapy known as a programmed death receptor-1 (PD-1) blocking antibody, was initially approved for the treatment of advanced melanoma in patients who had already tried other therapies [1][2].

Since its initial approval, Keytruda has received additional approvals from the FDA for the treatment of various types of cancer, including non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, and microsatellite instability-high (MSI-H) cancer [1][2].

It is important to note that while Keytruda has been shown to be effective in treating certain types of cancer, it is not appropriate for all patients and may have serious side effects [1]. Patients should consult with their healthcare providers to determine whether Keytruda is an appropriate treatment option for them.

Sources:

* [1] U.S. Food and Drug Administration. (2021). Keytruda (pembrolizumab) prescribing information. Retrieved from <https://www.fda.gov/media/86330/download>
* [2] DrugPatentWatch. (2021). Keytruda (pembrolizumab) patents. Retrieved from <https://www.drugpatentwatch.com/drugs/keytruda>